TY - JOUR
T1 - From Infection to Tumor
T2 - Exploring the Therapeutic Potential of Ciprofloxacin Derivatives as Anticancer Agents
AU - Hassan, Hesham M.
AU - Hassan, Roket
AU - Elmagzoub, Ranya Mohammed
AU - Al-Emam, Ahmed
AU - Kossenas, Konstantinos
AU - Abdel-Samea, Ahmed S.
AU - Khalifa, Hazim O.
AU - Akocak, Suleyman
AU - Bräse, Stefan
AU - Hashem, Hamada
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/1
Y1 - 2025/1
N2 - Ciprofloxacin, a widely used second-generation fluoroquinolone for treating bacterial infections, has recently shown notable anticancer properties. This review explores progress in developing ciprofloxacin derivatives with anticancer properties, emphasizing key structural changes that improve their therapeutic effectiveness by modifying the basic group at position 7, the carboxylic acid group at position 3, or both. It further investigates the mechanisms by which these derivatives fight cancer, such as inducing apoptosis, arresting the cell cycle, inhibiting topoisomerase I and II, preventing tubulin polymerization, suppressing interleukin 6, blocking thymidine phosphorylase, inhibiting multidrug resistance proteins, and hindering angiogenesis. Additionally, it outlines their future directions, such as enhancing their efficacy, selectivity, and investigating potential synergy with other chemotherapeutic agents, offering a promising avenue for developing new therapies for cancer.
AB - Ciprofloxacin, a widely used second-generation fluoroquinolone for treating bacterial infections, has recently shown notable anticancer properties. This review explores progress in developing ciprofloxacin derivatives with anticancer properties, emphasizing key structural changes that improve their therapeutic effectiveness by modifying the basic group at position 7, the carboxylic acid group at position 3, or both. It further investigates the mechanisms by which these derivatives fight cancer, such as inducing apoptosis, arresting the cell cycle, inhibiting topoisomerase I and II, preventing tubulin polymerization, suppressing interleukin 6, blocking thymidine phosphorylase, inhibiting multidrug resistance proteins, and hindering angiogenesis. Additionally, it outlines their future directions, such as enhancing their efficacy, selectivity, and investigating potential synergy with other chemotherapeutic agents, offering a promising avenue for developing new therapies for cancer.
KW - anticancer
KW - apoptosis inducers
KW - cell cycle arrest
KW - ciprofloxacin
KW - topoisomerases I and II inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85216242384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85216242384&partnerID=8YFLogxK
U2 - 10.3390/ph18010072
DO - 10.3390/ph18010072
M3 - Review article
AN - SCOPUS:85216242384
SN - 1424-8247
VL - 18
JO - Pharmaceuticals
JF - Pharmaceuticals
IS - 1
M1 - 72
ER -
